BAYZF Beyer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, and cosmetics in the dermatology, nutritional supplement, analgesic, digestive health, allergy, cold, foot care, and sun protection categories. The Crop Science segment offers crop protection products, seeds, non-agriculture pest control products. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to vets, farmers, and pet-owners. Bayer Aktiengesellschaft has a collaboration agreement with The University of Texas MD Anderson Cancer Center to develop cancer treatments, as well as Haplogen GmbH. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol GF:BAYN.
$61.15 Pink
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Large cap
GICS sector: Health Care
Industry: Drug Manufacturers—General
Index country: Germany
Country of incorporation: Germany
IPO date: 11/21/2018
Outstanding shares: 982,424,082
Average volume: 38,533
Market cap: $60,070,320,494
Current dividend yield: 0.00%
Sedol: B033630
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%